April 11, 2023
Company pursuing a highly differentiated small molecule MOS-118 in Metabolic Obstructive Sleep Apnea. New investors, Supermoon Capital and HTGF, join founding investor Forty51 Ventures to complete the Seed syndicate. Company will use the funds to file an IND in preparation for a proof of mechanism and proof of concept in the clinic. Basel, Switzerland, April...
Read More